Tern SVV Fund undertakes its first investment

TERN

Tern Plc (LON:TERN), the company focused on value creation from Internet of Things technology businesses, has noted that following the agreement for Tern to participate in the new Sure Valley Ventures UK Software Technology Fund, announced on 2 March 2022, the new SVV Fund has undertaken its first investment.

The SVV Fund has led a £2 million seed investment round, with the SVV Fund providing a £1 million investment in RETìníZE Limited, an award-winning creative-technology company based in Belfast, Northern Ireland.  RETìníZE is developing an innovative software product, Animotive, that is harnessing virtual reality technologies to transform the 3D animation production process.  The investment is designed to drive RETìníZE’s growth plan for the next two-years and the global rollout of Animotive.

Tern’s contribution to the SVV Fund’s investment in RETìníZE will be covered by the approximately £90,000 initially invested by Tern in the SVV Fund, as previously announced.

The SVV Fund are joined in RETìníZE’s investment round by investors from the UK, USA, Ireland and the Netherlands, including: TechStart Ventures, who are following on from their 2019 pre-seed investment; VGC Partners; Clarendon/Co-fund NI; Lonely Horse Investments; Bertram van Munster and Elise Doganieri, the multi Emmy award-winning producers behind the CBS hit show ‘the Amazing Race’; and Ben Morrow, Senior Product Manager, Adobe Aero (Adobe’s AR creation tool).

RETìníZE CEO, Phil Morrow, said: “We are thrilled to have Sure Valley on board as our lead investor – they have a deep knowledge of the creative tech sector and what impressed us most was the time they took to really understand and challenge our long-term goals and objectives.  This investment will supercharge our growth trajectory and will allow us to take Animotive to the international market.”

Sure Valley Ventures Principal, Isabelle O’Keeffe, said: “We are delighted to be able to support RETìníZE as the first investment of our recently launched software fund, as it enters this exciting new phase. We recognise that the immersive software sector is poised for exponential growth, and the plans that RETìníZE has for Animotive will position the company at the forefront of this expansion. We will continue to identify new opportunities in Metaverse, AI and Cybersecurity as we deploy our Fund II capital, with a focus on companies, like RETìníZE, which are bringing a disruptive innovation to market.”

Commenting, Al Sisto, CEO of Tern said: “We are delighted to see the SVV Fund make their first investment.  In RETìníZE they are investing in an exciting company developing innovative technology that fits very well with Tern’s existing participation in the virtual reality space. As a member of the SVV Fund’s Investor Committee, I look forward to working with RETìníZE, with a view to benefiting both RETìníZE and Tern’s wider network of companies.”

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Tern cuts H1 loss by 60% as portfolio growth and funding strengthen

Tern reduced its first-half loss by 60%, with net asset value improving and further fundraising strengthening the balance sheet. Additional funding has supported Talking Medicines and Device Authority, while continued progress across the portfolio provides further scope for value creation.

AI control of machines creates a new market for device trust

AI is beginning to control physical machines, increasing demand for technology that can verify device identity before those machines are allowed to act.

Peptide drug development expands beyond GLP-1

GLP-1 success is widening interest in peptide drug development, with the next phase focused on proving clinical value across new therapeutic areas.

Tern Plc announces 90% take-up of Open Offer

Tern Plc has received valid acceptances for 50.9 million Open Offer Shares, representing approximately 90% of the shares available. The fully underwritten offer will raise approximately £509,368 before expenses, with admission of the new shares expected on 24 September 2026.

Talking Medicines moves to capture pharma demand for better patient intelligence

Tighter US pharma advertising rules could increase demand for patient intelligence, supporting the relevance of Talking Medicines’ DrugVoice platform.

Tern portfolio company Talking Medicines launches ‘Intent to Prescribe’ DrugVoice application

Talking Medicines has launched a new DrugVoice application combining its Message Resonance Score™ with near-real-time point-of-care data to help pharmaceutical companies assess links between HCP message alignment and prescribing intent.

Search